These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 28691152

  • 1. Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT.
    Leon Rodriguez E, Rivera Franco MM, Perez Alvarez SI.
    Ann Hematol; 2017 Sep; 96(9):1525-1531. PubMed ID: 28691152
    [Abstract] [Full Text] [Related]

  • 2. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q, Liu H, Liang X, Yang T, Fan Z, Huang F, Ling Y, Liao X, Xuan L, Xu N, Xu X, Ye J, Liu Q.
    J Hematol Oncol; 2017 Jul 04; 10(1):135. PubMed ID: 28676100
    [Abstract] [Full Text] [Related]

  • 3. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
    Tang W, Wang L, Zhao WL, Chen YB, Shen ZX, Hu J.
    Biol Blood Marrow Transplant; 2011 Oct 04; 17(10):1555-61. PubMed ID: 21549217
    [Abstract] [Full Text] [Related]

  • 4. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
    Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D, Zhang Y, Huang F, Zhou H, Fan Z, Tu S, Li Y, Guo X, Yu G, Liu Q.
    J Hematol Oncol; 2013 Feb 08; 6():15. PubMed ID: 23394705
    [Abstract] [Full Text] [Related]

  • 5. [Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation].
    Chen Y, Xu L, Liu D, Liu K, Chen H, Zhang X, Wang F, Wang J, Wang Y, Han W, Chen Y, Yan C, Zhao T, Huang X.
    Zhonghua Nei Ke Za Zhi; 2014 Sep 08; 53(9):710-4. PubMed ID: 25511404
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia.
    Xiao F, Guo H, Yan X, Qi M, Zhang J.
    Transpl Immunol; 2024 Jun 08; 84():102037. PubMed ID: 38499049
    [Abstract] [Full Text] [Related]

  • 7. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct 08; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 8. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
    Gao L, Wen Q, Chen X, Liu Y, Zhang C, Gao L, Kong P, Zhang Y, Li Y, Liu J, Wang Q, Su Y, Wang C, Wang S, Zeng Y, Sun A, Du X, Zeng D, Liu H, Peng X, Zhang X.
    Biol Blood Marrow Transplant; 2014 Dec 08; 20(12):1932-9. PubMed ID: 25109850
    [Abstract] [Full Text] [Related]

  • 9. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE.
    Biol Blood Marrow Transplant; 2015 May 08; 21(5):906-12. PubMed ID: 25667989
    [Abstract] [Full Text] [Related]

  • 10. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
    Sun AN, Wu DP, Wang Y, Qiu HY, Jin ZM, Miao M, Tang XW, Fu ZZ, Ma X, Han Y, He GS, Chen SN, Xue SL, Zhao Y.
    Ai Zheng; 2006 Aug 08; 25(8):1019-22. PubMed ID: 16965686
    [Abstract] [Full Text] [Related]

  • 11. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
    Liu H, Fan ZP, Jiang QL, Huang F, Zhou HS, Zhang X, Yu GP, Wu MQ, Sun J, Liu QF.
    Zhonghua Nei Ke Za Zhi; 2012 Nov 08; 51(11):880-4. PubMed ID: 23291027
    [Abstract] [Full Text] [Related]

  • 12. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct 08; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 13. A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
    Wang J, Zhao J, Fei X, Yin Y, Cheng H, Zhang W, Gu J, Yang F, Yang Y, Xue S, Tian Z, He J, Zhang S, Wang X.
    Medicine (Baltimore); 2018 Apr 08; 97(17):e0228. PubMed ID: 29702970
    [Abstract] [Full Text] [Related]

  • 14. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun 08; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 15. Allogeneic bone marrow transplantation for chronic myeloid leukemia using HLA identical sibling donors primed with G-CSF.
    Chen HR, Ji SQ, Wang HX, Yan HM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug 08; 10(4):340-6. PubMed ID: 12513770
    [Abstract] [Full Text] [Related]

  • 16. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan 08; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 17. [A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia].
    Nakamae H, Terada Y, Nakane T, Koh H, Nakamae M, Aimoto R, Hirose A, Hayashi Y, Nishimoto M, Inoue E, Yoshimura T, Inoue A, Koh KR, Yamane T, Hino M.
    Gan To Kagaku Ryoho; 2010 Sep 08; 37(9):1691-5. PubMed ID: 20841930
    [Abstract] [Full Text] [Related]

  • 18. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.
    Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Mordini N, Berisso G, Bregante S, Frassoni F, Sessarego M, Fugazza G, Di Stefano F, Pitto A, Bacigalupo A.
    Br J Haematol; 2000 Jun 08; 109(4):716-21. PubMed ID: 10929020
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M.
    J Clin Oncol; 2013 Oct 01; 31(28):3549-56. PubMed ID: 23980086
    [Abstract] [Full Text] [Related]

  • 20. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH, Zhang C, Zhang X, Gao L, Gao L, Kong PY, Peng XG, Qi DG, Sun AH, Zeng DF, Liu H, Gong Y, Wang QY.
    Biol Blood Marrow Transplant; 2009 Feb 01; 15(2):266-73. PubMed ID: 19167687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.